New Interleukin-23 Pathway Inhibitors in Dermatology

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

(2010) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Ustekinumab in the treatment of palmoplantar pustulosis

(2010) S. Gerdes et al.   BRITISH JOURNAL OF DERMATOLOGY

Should ustekinumab really be used as first-line biological therapy in pityriasis rubra pilaris?

(2010) R. Balestri et al.   BRITISH JOURNAL OF DERMATOLOGY

Treatment of pityriasis rubra pilaris with ustekinumab

(2010) J. Wohlrab et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis

(2010) E. Daudén et al.   BRITISH JOURNAL OF DERMATOLOGY

Th17/Th1 phenotype in demyelinating disease

(2010) L.J. Edwards et al.   CYTOKINE

Mycobacterium bovis BCG-itis and Cervical Lymphadenitis due to Salmonella enteritidis in a Patient with Complete Interleukin-12/-23 Receptor β1 Deficiency

(2010) E. van de Vosse et al.   INFECTION

Bacille Calmette–Guérin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families

(2010) Sigifredo Pedraza-Sánchez et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

IL-23 Receptor Regulates Unconventional IL-17–Producing T Cells That Control Bacterial Infections

(2010) Lorena Riol-Blanco et al.   JOURNAL OF IMMUNOLOGY

Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab

(2010) Jinquan Luo et al.   JOURNAL OF MOLECULAR BIOLOGY

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

(2010) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community

(2010) A Menter et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis

(2010) Mona Gandhi et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus

(2010) Kamini Shah et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders

(2009) S. Goriely et al.   ALLERGY

Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis

(2009) James V Scanlon et al.   ANNALS OF PHARMACOTHERAPY

Ustekinumab

(2009) Juliane Weber et al.   BIODRUGS

Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis

(2009) Y. Zhao et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

(2009) M. Lebwohl et al.   BRITISH JOURNAL OF DERMATOLOGY

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

(2009) Marcin Kortylewski et al.   CANCER CELL

Cytokine gene-mediated immunotherapy: Current status and future perspectives

(2009) Masahisa Jinushi et al.   CANCER SCIENCE

Serum cytokines and growth factor levels in Japanese patients with psoriasis

(2009) H. Takahashi et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Long-term efficacy of biologics in dermatology

(2009) Leslie Castelo-Soccio et al.   Dermatologic Therapy

New biologics for psoriasis and psoriatic arthritis

(2009) Mariya Rozenblit et al.   Dermatologic Therapy

Ustekinumab

(2009) Anna L. Chien et al.   DRUGS

Differential regulation of interleukin 17 and interferon   production in inflammatory bowel disease

(2009) L. Rovedatti et al.   GUT

Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans

(2009) Lyudmila Lyakh et al.   IMMUNOLOGICAL REVIEWS

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease

(2009) Bruce E. Sands et al.   INFLAMMATORY BOWEL DISEASES

Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

(2009) Honghui Zhou et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Etanercept: Efficacy and safety

(2009) R Jiménez-Puya et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab for psoriatic arthritis

(2009) Raquel S Cuchacovich et al.   LANCET

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Immunology's quiet upheaval

(2009) Ken Garber   NATURE BIOTECHNOLOGY

New insights into the pathogenesis and genetics of psoriatic arthritis

(2009) Kristine E Nograles et al.   Nature clinical practice. Rheumatology

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet’s disease

(2008) W. Lew et al.   BRITISH JOURNAL OF DERMATOLOGY

Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity

(2008) Chun Kwok Wong et al.   CLINICAL IMMUNOLOGY

Induction, function and regulation of IL-17-producing T cells

(2008) Kingston H. G. Mills   EUROPEAN JOURNAL OF IMMUNOLOGY

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Th17 cells: a new fate for differentiating helper T cells

(2008) Zhi Chen et al.   IMMUNOLOGIC RESEARCH

IL-23 and TH17-mediated inflammation in human allergic contact dermatitis

(2008) Jeppe Madura Larsen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Th17 cells: A new therapeutic target in inflammatory dermatoses

(2008) Adam Asarch et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Th17 cells: A new paradigm for cutaneous inflammation

(2008) Adam Asarch et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Increased Serum Soluble OX40 in Patients with Systemic Sclerosis

(2008) Kazuhiro Komura et al.   JOURNAL OF RHEUMATOLOGY

Ustekinumab for chronic plaque psoriasis

(2008) Brenda L Bartlett et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

IL-21 and TGF-β are required for differentiation of human TH17 cells

(2008) Li Yang et al.   NATURE

Psoriatic arthritis: genetic susceptibility and pharmacogenetics

(2008) Proton Rahman et al.   PHARMACOGENOMICS